The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas

T. Murata, R. Nagai, Tatsuro Ishibashi, H. Inomata, K. Ikeda, S. Horiuchi

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Both advanced glycation end products and vascular endothelial growth factor are believed to play a role in the pathogenesis of diabetic retinopathy. It is known that vascular endothelial growth factor causes retinal neovascularization and a breakdown of the blood-retinal barrier: how advanced glycation end products affect the retina, however, remains largely unclear. The substance N(ε)-(carboxymethyl)lysine is a major immunologic epitope, i.e. a dominant advanced glycation end products antigen. We generated an anti-N(ε)-(carboxymethyl)lysine antibody to investigate the relationship between the localization of advanced glycation end products and that of vascular endothelial growth factor in 27 human diabetic retinas by immunohistochemistry. Nine control retinas were also examined. In all 27 diabetic retinas, N(ε)-(carboxymethyl)lysine was located in the thickened vascular wall. In 19 of the 27 retinas, strand-shaped N(ε)- (carboxymethyl)lysine immunoreactivity was also observed around the vessels. In all 27 diabetic retinas, vascular endothelial growth factor revealed a distribution pattern similar to that of N(ε)-(carboxymethyl)lysine. Vascular endothelial growth factor was also located in the vascular wall and in the perivascular area. Neither N(ε)-(carboxymethyl)lysine nor vascular endothelial growth factor immunoreactivity was detected in the 9 control retinas. Vessels with positive immunoreactivity for N(ε)- (carboxymethyl)lysine and/or vascular endothelial growth factor were counted. A general association was noted between accumulation of N(ε)- (carboxymethyl)lysine and expression of vascular endothelial growth factor in the eyes with non-proliferative diabetic retinopathy (p < 0.01) and proliferative diabetic retinopathy (p < 0.05).

Original languageEnglish
Pages (from-to)764-769
Number of pages6
JournalDiabetologia
Volume40
Issue number7
DOIs
Publication statusPublished - Aug 2 1997

Fingerprint

Advanced Glycosylation End Products
Vascular Endothelial Growth Factor A
Retina
Diabetic Retinopathy
Blood Vessels
Blood-Retinal Barrier
Retinal Neovascularization
N(6)-carboxymethyllysine
human VEGFA protein
Epitopes
Immunohistochemistry
Antigens
Antibodies

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. / Murata, T.; Nagai, R.; Ishibashi, Tatsuro; Inomata, H.; Ikeda, K.; Horiuchi, S.

In: Diabetologia, Vol. 40, No. 7, 02.08.1997, p. 764-769.

Research output: Contribution to journalArticle

@article{16796bb1856c409c8616dc5869434796,
title = "The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas",
abstract = "Both advanced glycation end products and vascular endothelial growth factor are believed to play a role in the pathogenesis of diabetic retinopathy. It is known that vascular endothelial growth factor causes retinal neovascularization and a breakdown of the blood-retinal barrier: how advanced glycation end products affect the retina, however, remains largely unclear. The substance N(ε)-(carboxymethyl)lysine is a major immunologic epitope, i.e. a dominant advanced glycation end products antigen. We generated an anti-N(ε)-(carboxymethyl)lysine antibody to investigate the relationship between the localization of advanced glycation end products and that of vascular endothelial growth factor in 27 human diabetic retinas by immunohistochemistry. Nine control retinas were also examined. In all 27 diabetic retinas, N(ε)-(carboxymethyl)lysine was located in the thickened vascular wall. In 19 of the 27 retinas, strand-shaped N(ε)- (carboxymethyl)lysine immunoreactivity was also observed around the vessels. In all 27 diabetic retinas, vascular endothelial growth factor revealed a distribution pattern similar to that of N(ε)-(carboxymethyl)lysine. Vascular endothelial growth factor was also located in the vascular wall and in the perivascular area. Neither N(ε)-(carboxymethyl)lysine nor vascular endothelial growth factor immunoreactivity was detected in the 9 control retinas. Vessels with positive immunoreactivity for N(ε)- (carboxymethyl)lysine and/or vascular endothelial growth factor were counted. A general association was noted between accumulation of N(ε)- (carboxymethyl)lysine and expression of vascular endothelial growth factor in the eyes with non-proliferative diabetic retinopathy (p < 0.01) and proliferative diabetic retinopathy (p < 0.05).",
author = "T. Murata and R. Nagai and Tatsuro Ishibashi and H. Inomata and K. Ikeda and S. Horiuchi",
year = "1997",
month = "8",
day = "2",
doi = "10.1007/s001250050747",
language = "English",
volume = "40",
pages = "764--769",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas

AU - Murata, T.

AU - Nagai, R.

AU - Ishibashi, Tatsuro

AU - Inomata, H.

AU - Ikeda, K.

AU - Horiuchi, S.

PY - 1997/8/2

Y1 - 1997/8/2

N2 - Both advanced glycation end products and vascular endothelial growth factor are believed to play a role in the pathogenesis of diabetic retinopathy. It is known that vascular endothelial growth factor causes retinal neovascularization and a breakdown of the blood-retinal barrier: how advanced glycation end products affect the retina, however, remains largely unclear. The substance N(ε)-(carboxymethyl)lysine is a major immunologic epitope, i.e. a dominant advanced glycation end products antigen. We generated an anti-N(ε)-(carboxymethyl)lysine antibody to investigate the relationship between the localization of advanced glycation end products and that of vascular endothelial growth factor in 27 human diabetic retinas by immunohistochemistry. Nine control retinas were also examined. In all 27 diabetic retinas, N(ε)-(carboxymethyl)lysine was located in the thickened vascular wall. In 19 of the 27 retinas, strand-shaped N(ε)- (carboxymethyl)lysine immunoreactivity was also observed around the vessels. In all 27 diabetic retinas, vascular endothelial growth factor revealed a distribution pattern similar to that of N(ε)-(carboxymethyl)lysine. Vascular endothelial growth factor was also located in the vascular wall and in the perivascular area. Neither N(ε)-(carboxymethyl)lysine nor vascular endothelial growth factor immunoreactivity was detected in the 9 control retinas. Vessels with positive immunoreactivity for N(ε)- (carboxymethyl)lysine and/or vascular endothelial growth factor were counted. A general association was noted between accumulation of N(ε)- (carboxymethyl)lysine and expression of vascular endothelial growth factor in the eyes with non-proliferative diabetic retinopathy (p < 0.01) and proliferative diabetic retinopathy (p < 0.05).

AB - Both advanced glycation end products and vascular endothelial growth factor are believed to play a role in the pathogenesis of diabetic retinopathy. It is known that vascular endothelial growth factor causes retinal neovascularization and a breakdown of the blood-retinal barrier: how advanced glycation end products affect the retina, however, remains largely unclear. The substance N(ε)-(carboxymethyl)lysine is a major immunologic epitope, i.e. a dominant advanced glycation end products antigen. We generated an anti-N(ε)-(carboxymethyl)lysine antibody to investigate the relationship between the localization of advanced glycation end products and that of vascular endothelial growth factor in 27 human diabetic retinas by immunohistochemistry. Nine control retinas were also examined. In all 27 diabetic retinas, N(ε)-(carboxymethyl)lysine was located in the thickened vascular wall. In 19 of the 27 retinas, strand-shaped N(ε)- (carboxymethyl)lysine immunoreactivity was also observed around the vessels. In all 27 diabetic retinas, vascular endothelial growth factor revealed a distribution pattern similar to that of N(ε)-(carboxymethyl)lysine. Vascular endothelial growth factor was also located in the vascular wall and in the perivascular area. Neither N(ε)-(carboxymethyl)lysine nor vascular endothelial growth factor immunoreactivity was detected in the 9 control retinas. Vessels with positive immunoreactivity for N(ε)- (carboxymethyl)lysine and/or vascular endothelial growth factor were counted. A general association was noted between accumulation of N(ε)- (carboxymethyl)lysine and expression of vascular endothelial growth factor in the eyes with non-proliferative diabetic retinopathy (p < 0.01) and proliferative diabetic retinopathy (p < 0.05).

UR - http://www.scopus.com/inward/record.url?scp=0030805762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030805762&partnerID=8YFLogxK

U2 - 10.1007/s001250050747

DO - 10.1007/s001250050747

M3 - Article

VL - 40

SP - 764

EP - 769

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 7

ER -